A novel first-line maintenance therapy regimen improved outcomes for patients with extensive-stage small cell lung cancer, according to study results scheduled for presentation at ASCO Annual ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled Phase 2/3 ...

A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed by scientists at Institut Curie, the ...

Long considered mere auxiliary cells, their therapeutic potential has been considered of secondary importance. But the scientists have discovered that they also have a strong killing capacity ...

Patients with intermediate stage primary liver cancer who received a vaccine of dendritic cells saw a longer time without tumour progression in response to standard treatment according to a new study ...

More than 25,000 patients have been treated with Kite’s CAR T-cell therapies, but the number of eligible patients who could potentially benefit from this one-time treatment is much greater.